[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"attrv-pn\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:attrv-pn":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":66},"100551878","non-interventional-study-of-patients-with-transthyretin-attr-amyloidosis-100551878",false,"NCT06465810","Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis","A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) Amyloidosis","MaesTTRo","Inclusion Criteria:\n\n* Patient willing and able to provide written informed consent to participate in the study\n* Confirmed diagnosis of amyloid transthyretin (ATTR) amyloidosis\n* Aged ≥18 years at the time of signing the informed consent\n* Patient willing and able to participate in collection of electronic patient reported outcomes (PROs)\n\nExclusion Criteria:\n\n* Concurrent participation in any interventional trial for ATTR amyloidosis\n* Involvement in the planning and\u002For conduct of the current study\n* Patients with evidence of primary or light chain amyloidosis (AL) or serum protein A amyloidosis (AA)\n* Asymptomatic patients with ATTR amyloidosis and asymptomatic ATTR mutation carriers","ALL","18 Years","130 Years",{"count":21,"type":22},1850,"ESTIMATED","OBSERVATIONAL","The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.",[26,27,28,29,30,31],"Transthyretin Amyloidosis","ATTR-CM","ATTRv-PN","ATTR","ATTR-Mixed","hATTR",[33,34,35,36,37,38,39,40,41,42,43,29,44,45,46,47,48,49,50,51,52,53],"Amyloidosis","Transthyretin","Hereditary transthyretin-mediated (hATTR) amyloidosis","hATTR amyloidosis","Hereditary ATTR amyloidosis","Wild-type amyloidosis","wtATTR amyloidosis","ATTRv amyloidosis","ATTRwt amyloidosis","Polyneuropathy","Familial amyloid polyneuropathies","Transthyretin amyloidosis","TTR-mediated amyloidosis","Polyneuropathies","Amyloid neuropathies","Amyloid neuropathies, familial","Amyloidosis, familial","Eplontersen","Non-interventional","Observational","Real-world","RECRUITING","2026-06-19",{"date":57,"type":58},"2026-06-23","ACTUAL",{"date":60,"type":58},"2024-06-25",{"date":62,"type":22},"2031-12-29",{"name":64,"class":65},"AstraZeneca","INDUSTRY",74]